



Wound Healing Society Recognizes Scientific Research at RegenesiS Biomedical

Blue Ribbon awarded for research on pulsed radio frequency energy gene expression

Scottsdale, Arizona, April 11, 2011 -- RegenesiS Biomedical, Inc., a medical technology company that markets the Provant[®] Therapy System, announced today the Wound Healing Society has again awarded its prestigious Blue Ribbon Award in recognition of scientific research at RegenesiS. This is the fourth consecutive year that RegenesiS has earned a top award.

The Blue Ribbon Industrial Research and Development Award is presented for demonstrating the biological mechanisms of action or efficacy of therapies. The competition recognizes the best product-oriented research within the corporate world. The RegenesiS abstract is titled “The Effect of Pulsed Radio Frequency Electromagnetic Fields on Inflammatory and Angiogenesis Gene Expression in Human Diploid Fibroblasts and Keratinocytes.” The award will be made at the spring 2011 Symposium on Advanced Wound Care (SAWC) in Dallas, Texas. During the April 14-17 conference, over 2,500 wound care clinician attendees are expected, and over 80 sessions, 150 speakers, and 200 exhibiting companies.

“The findings of our laboratory research on the effects of Provant Therapy support the results clinicians see in their patients,” said Virginia Rybski, President and CEO of RegenesiS Biomedical. “We are truly honored that our research on gene expression is recognized by the Wound Healing Society.”

About RegenesiS Biomedical

RegenesiS Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. RegenesiS developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

About the Provant[®] Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: RegenesiS Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesibio.com
480-970-4970 phone

SOURCE: RegenesiS Biomedical Inc.